Cargando…
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice
INTRODUCTION: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975056/ https://www.ncbi.nlm.nih.gov/pubmed/29854936 http://dx.doi.org/10.1016/j.trci.2015.08.001 |
_version_ | 1783326939340079104 |
---|---|
author | Majid, Tabassum Griffin, Deric Criss, Zachary Jarpe, Matthew Pautler, Robia G. |
author_facet | Majid, Tabassum Griffin, Deric Criss, Zachary Jarpe, Matthew Pautler, Robia G. |
author_sort | Majid, Tabassum |
collection | PubMed |
description | INTRODUCTION: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmortem tissue samples from patients. However, HDAC6 inhibitors have had limited success preclinically due to low blood-brain barrier penetration. METHOD: We investigated a specific, potent HDAC6 inhibitor (ACY-738) in a mouse model of AD. We determined the effects of ACY-738 treatment on axonal transport, behavior, and pathology in amyloid precursor protein/presenilin 1 mice. RESULTS: We demonstrated improvements in in vivo axonal transport in two treatment groups as a result of ACY-738 brain levels. We also demonstrated recovery of short-term learning and memory deficits, hyperactivity, and modifications of tau and tubulin. DISCUSSION: Our findings implicate specific, targeted HDAC6 inhibitors as potential therapeutics and demonstrate that further investigations are warranted into effects of HDAC6 inhibitors in AD. |
format | Online Article Text |
id | pubmed-5975056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-59750562018-05-31 Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice Majid, Tabassum Griffin, Deric Criss, Zachary Jarpe, Matthew Pautler, Robia G. Alzheimers Dement (N Y) Featured Article INTRODUCTION: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmortem tissue samples from patients. However, HDAC6 inhibitors have had limited success preclinically due to low blood-brain barrier penetration. METHOD: We investigated a specific, potent HDAC6 inhibitor (ACY-738) in a mouse model of AD. We determined the effects of ACY-738 treatment on axonal transport, behavior, and pathology in amyloid precursor protein/presenilin 1 mice. RESULTS: We demonstrated improvements in in vivo axonal transport in two treatment groups as a result of ACY-738 brain levels. We also demonstrated recovery of short-term learning and memory deficits, hyperactivity, and modifications of tau and tubulin. DISCUSSION: Our findings implicate specific, targeted HDAC6 inhibitors as potential therapeutics and demonstrate that further investigations are warranted into effects of HDAC6 inhibitors in AD. Elsevier 2015-10-11 /pmc/articles/PMC5975056/ /pubmed/29854936 http://dx.doi.org/10.1016/j.trci.2015.08.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Featured Article Majid, Tabassum Griffin, Deric Criss, Zachary Jarpe, Matthew Pautler, Robia G. Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice |
title | Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice |
title_full | Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice |
title_fullStr | Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice |
title_full_unstemmed | Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice |
title_short | Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice |
title_sort | pharmocologic treatment with histone deacetylase 6 inhibitor (acy-738) recovers alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (app/ps1) mice |
topic | Featured Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975056/ https://www.ncbi.nlm.nih.gov/pubmed/29854936 http://dx.doi.org/10.1016/j.trci.2015.08.001 |
work_keys_str_mv | AT majidtabassum pharmocologictreatmentwithhistonedeacetylase6inhibitoracy738recoversalzheimersdiseasephenotypeinamyloidprecursorproteinpresenilin1appps1mice AT griffinderic pharmocologictreatmentwithhistonedeacetylase6inhibitoracy738recoversalzheimersdiseasephenotypeinamyloidprecursorproteinpresenilin1appps1mice AT crisszachary pharmocologictreatmentwithhistonedeacetylase6inhibitoracy738recoversalzheimersdiseasephenotypeinamyloidprecursorproteinpresenilin1appps1mice AT jarpematthew pharmocologictreatmentwithhistonedeacetylase6inhibitoracy738recoversalzheimersdiseasephenotypeinamyloidprecursorproteinpresenilin1appps1mice AT pautlerrobiag pharmocologictreatmentwithhistonedeacetylase6inhibitoracy738recoversalzheimersdiseasephenotypeinamyloidprecursorproteinpresenilin1appps1mice |